Source: Annual Congress 2005 - Basic mechanisms in asthma and COPD: new insights
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Gagliardo, F. Pompeo, A. M. Merendino, M. Gjomarkaj, I. Vachier, J. Bousquet, G. Bonsignore, P. Chanez (Palermo, Italy; , ; Montpellier, France). Role of IκB kinases (IKKs) α and β in severe asthma and COPD. Eur Respir J 2005; 26: Suppl. 49, 142

Member's Comments

No comment yet.

Related content which might interest you: MAPKAP kinase 2(MK2) expression is associated with severe asthma Source: International Congress 2016 – Mechanisms of disease Year: 2016 Increased activation of p38 MAPK in COPD Source: Eur Respir J 2008; 31: 62-69 Year: 2008 Role of the kinase-dependent functions of RIPK1 in COPD Source: Virtual Congress 2020 – Physiological and cellular mechanisms affecting pulmonary pathologies Year: 2020 Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 Systemic inhibition of p38 MAPK improves lung function and inflammatory markers in moderate-severe COPD Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 JAK/STATs in asthma and COPD Source: Annual Congress 2004 - Transcription factors in airway disease Year: 2004 Enrichment of the Janus kinase (JAK) activation signature in severe asthma sputum: Correlation with IL-13 expression Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Targeting the mTOR signaling pathway to inhibit lung cell senescence in chronic obstructive pulmonary disease (COPD) Source: ERS Lung Science Conference 2017 Year: 2017 Expression of phosphorylated p38 MAPK in the lung of smokers with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 582s Year: 2006 The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Activation of the inflammasome pathway during exacerbations of COPD Source: Annual Congress 2011 - Recent developments in COPD Year: 2011 Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations Source: Eur Respir J 2016; 47: 783-791 Year: 2016 Pro-inflammatory role of the nuclear kinase MSK1 in asthma Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Anti IL-17 with or without Rho kinase inhibitor in mice with chronic allergic pulmonary inflammation Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 Increased activity of Lyn tyrosine kinase causes multiple chronic obstructive pulmonary disease-like changes in mouse Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Corticosteroids: use and insensitivity in severe asthma Source: Eur Respir Mon 2011; 51: 236-252 Year: 2011 Syk is downstream of ICAM-1 and mediates human rhinovirus (HRV) activation of p38 MAP kinase in airway epithelial cells Source: Annual Congress 2006 - Airway epithelial cells in inflammation Year: 2006 The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1426-1433 Year: 2015